@FiercePharma: CEO compensation down 25%. Report | Follow @FiercePharma
> Abbott Laboratories' Humira and Enbrel, from Pfizer and Amgen, should be the first choices for treating patients with psoriatic arthritis, Britain's cost-effectiveness watchdog determined, leaving Merck and Johnson & Johnson's Remicade for second-line use. Report
> Irish drugmaker Elan has quietly given Johnson & Johnson the right to acquire its 49.9 percent stake in their joint Alzheimer's disease venture--a move that could deter potential bidders for Elan. Report
> Aggressive treatment with Novartis' Diovan and Starlix failed to prevent diabetes and its cardiovascular effects in overweight patients with poor sugar metabolism. Report
> Genzyme notified customers using its drug Cerezyme that an impurity was found in a vial manufactured at the company's plant in Waterford, Ireland, but the problem has already been addressed and cleared by the FDA. Report
> The Medical Council of India has proposed penal punishment for doctors accepting cash or any other gifts from drugmakers, although action would depend on individual states and the willingness of their medical councils to pursue action. Report
Biotech News
@FierceBiotech: MiddleBrook Pharma plans massive layoffs, CEO resigns. Report | Follow @FierceBiotech
@JohnCFierce: Find it hard to believe Arena would go it alone on obesity drug launch. Sounds like talk to me, aimed at better deal terms. Follow @JohnCFierce
> MannKind's inhaled insulin drug Afrezza delayed. Story
> Portola, Merck report postitive betrixaban results. Item
> NGM Biopharmaceuticals today announced it has closed the first tranche of a $51 million Series B round of financing with the help of Column Group, Tichenor Ventures, Prospect Venture Partners, Rho Ventures and other new and existing investors. Article
> Rhythm Pharma raises $21 million for metabolic diseases. Report
> FDA delays Amylin's Byetta LAR. Story
Biotech IT News
> iPhone app manages clinical trial images. Story
> Unified takes on integrated in e-clinical systems. Item
> Gartner checks Medidata adverse event module. Report
And Finally... While cosmetic surgery has been on the decline, less-expensive non-surgical treatments like Botox have held steady. Report